专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012092532A2 PROTEIN BIOMARKERS OF LATE STAGE BREAST CANCER 审中-公开
标题翻译：蛋白质乳腺癌生物标志物
公开(公告)号：WO2012092532A2
公开(公告)日：2012-07-05
申请号：PCT/US2011068000
申请日：2011-12-29
申请人： EXPRESSION PATHOLOGY INC , KRIZMAN DAVID B , DARFLER MARLENE M , CONRADS THOMAS P , HOOD BRIAN L , BATEMAN NICHOLAS W
发明人： KRIZMAN DAVID B , DARFLER MARLENE M , CONRADS THOMAS P , HOOD BRIAN L , BATEMAN NICHOLAS W
IPC分类号： C12Q1/37
CPC分类号： G01N33/57415 , G01N2800/52 , G01N2800/56
摘要： This patent application discloses and describes proteins found to be differentially expressed between primary tumor breast cancer cells histologicaly defined as early stage (stage 0) breast cancer and primary breast cancer cells histologicaly defined as late stage (stage 3) breast cancer. These proteins can be used either individually or in specific combinations in diagnostic and prognostic protein assays on various biological samples from breast cancer patients to indicate the that a breast cancer patient's cancer is in an early, non- aggressive stage or in a late, aggressive stage. Determination of differential expression of these proteins can also be useful for indicating additional therapies to combat the aggressiveness of late stage breast cancer. The full length intact proteins can be assayed or peptides derived from these proteins can be assayed as reporters for these proteins. These proteins can also be identified as "companion diagnostic" proteins, wherein the differentially expressed proteins that are used as diagnostic and prognostic indicators can also be used as targets for therapeutic intervention of breast cancer. Also disclosed and described herein are isotope labeled versions of peptides from the proteins.
摘要翻译：该专利申请公开并描述了被定义为早期阶段（阶段0）乳腺癌的原发肿瘤乳腺癌细胞组织学和定义为晚期（阶段3）乳腺癌的原发性乳腺癌细胞组织学之间差异表达的蛋白质。这些蛋白质可以在乳腺癌患者的各种生物样品的诊断和预后蛋白测定中单独使用或以特定组合使用，以表明乳腺癌患者的癌症处于早期，非侵袭性阶段或晚期侵袭阶段。确定这些蛋白质的差异表达也可用于指示其他治疗方法以抵抗晚期乳腺癌的侵袭性。可以测定全长完整蛋白质，或者可以将这些蛋白质衍生的肽作为这些蛋白质的报告物进行测定。这些蛋白质也可以被鉴定为“伴侣诊断”蛋白质，其中用作诊断和预后指标的差异表达的蛋白质也可以用作乳腺癌的治疗干预的靶标。本文还公开和描述的是来自蛋白质的肽的同位素标记形式。

2. 发明申请

WO2008097229A1 METHOD FOR SPECTROSCOPIC QUANTITATION OF HER-2 IN BIOLOGICAL SAMPLES 审中-公开
标题翻译：用于生物样品中HER-2的光谱定量的方法
公开(公告)号：WO2008097229A1
公开(公告)日：2008-08-14
申请号：PCT/US2007/003478
申请日：2007-02-09
申请人： THE GOVERNMENT OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES , CONRADS, Thomas, P. , VEENSTRA, Timothy, D. , HOOD, Brian, L. , KRIZMAN, David, B. , DARFLER, Marlene, M.
发明人： CONRADS, Thomas, P. , VEENSTRA, Timothy, D. , HOOD, Brian, L. , KRIZMAN, David, B. , DARFLER, Marlene, M.
IPC分类号： G01N33/574 , G01N33/68 , G01N33/74
CPC分类号： G01N33/57484 , G01N33/6872
摘要： Disclosed are methods for the detection of HER-2 in a biological sample using mass spectrometry. Specifically, these methods detect a cysteine-free HER-2 fragment peptide in the biological sample. The presence of HER-2 in a biological sample can be used to determine if a subject has a HER-2 associated cancer. The presence of HER-2 associated cancer can be used to determine if a subject would benefit from a HER-2 targeted therapy, such as an anti-HER-2 antibody. In one aspect, these methods can be used to quantify HER-2 in a biological sample via mass spectrometry by using an optionally isotopically labeled peptide standard.
摘要翻译：公开了使用质谱法检测生物样品中的HER-2的方法。具体地，这些方法检测生物样品中的半胱氨酸的HER-2片段肽。可以使用生物样品中HER-2的存在来确定受试者是否具有HER-2相关癌症。可以使用HER-2相关癌症的存在来确定受试者是否将受益于HER-2靶向治疗，例如抗HER-2抗体。一方面，这些方法可用于通过使用任选的同位素标记的肽标准通过质谱法定量生物样品中的HER-2。

3. 发明申请

WO2012092529A2 PROTEIN BIOMARKERS OF RECURRENT BREAST CANCER 审中-公开
标题翻译：乳腺癌的蛋白质生物标志物
公开(公告)号：WO2012092529A2
公开(公告)日：2012-07-05
申请号：PCT/US2011/067996
申请日：2011-12-29
申请人： EXPRESSION PATHOLOGY, INC. , KRIZMAN, David, B. , DARFLER, Marlene, M. , CONRADS, Thomas, P. , HOOD, Brian, L. , BATEMAN, Nicholas, W.
发明人： KRIZMAN, David, B. , DARFLER, Marlene, M. , CONRADS, Thomas, P. , HOOD, Brian, L. , BATEMAN, Nicholas, W.
IPC分类号： C12Q1/37
CPC分类号： G01N33/57415 , C12Q1/6886 , C12Q2600/118 , C12Q2600/156 , G01N2800/52
摘要： This patent application discloses and describes proteins found to be differentially expressed between primary tumor breast cancer cells that did not give rise to recurrent breast cancer disease after initial diagnosis and primary breast cancer cells that did give rise to recurrent breast cancer disease after initial diagnosis. These proteins can be used either individually or in specific combinations in diagnostic and prognostic protein assays on various biological samples from breast cancer patients to indicate the likelihood that a breast cancer patient's cancer will recur after initial diagnosis and treatment. Determination of differential expression of these proteins can also be useful for indicating additional therapies to combat the likelihood of recurrent breast cancer. The full length intact proteins can be assayed or peptides derived from these proteins can be assayed as reporters for these proteins. These proteins can also be identified as "companion diagnostic" proteins, wherein the differentially expressed proteins that arc used as diagnostic and prognostic indicators can also be used as targets for therapeutic intervention of breast cancer. Also disclosed and described herein are isotope labeled versions of peptides from the proteins.
摘要翻译：该专利申请公开并描述了在初步诊断后不会引起复发性乳腺癌疾病的原发性乳腺癌细胞和初次诊断后引起复发性乳腺癌疾病的原发性乳腺癌细胞之间发现差异表达的蛋白质。这些蛋白质可以在乳腺癌患者的各种生物样品的诊断和预后蛋白质测定中单独使用或以特定组合使用，以指示乳腺癌患者的癌症在初步诊断和治疗后将复发的可能性。确定这些蛋白质的差异表达也可用于指示额外的治疗方法来抵抗复发性乳腺癌的可能性。可以测定全长完整蛋白质，或者可以将这些蛋白质衍生的肽作为这些蛋白质的报告物进行测定。这些蛋白质也可以被鉴定为“伴侣诊断”蛋白质，其中用作诊断和预后指标的差异表达的蛋白质也可以用作乳腺癌的治疗干预的靶标。本文还公开和描述的是来自蛋白质的肽的同位素标记形式。

4. 发明申请

WO2012092532A3 PROTEIN BIOMARKERS OF LATE STAGE BREAST CANCER 审中-公开
公开(公告)号：WO2012092532A3
公开(公告)日：2012-07-05
申请号：PCT/US2011/068000
申请日：2011-12-29
申请人： EXPRESSION PATHOLOGY, INC. , KRIZMAN, David, B. , DARFLER, Marlene, M. , CONRADS, Thomas, P. , HOOD, Brian, L. , BATEMAN, Nicholas, W.
发明人： KRIZMAN, David, B. , DARFLER, Marlene, M. , CONRADS, Thomas, P. , HOOD, Brian, L. , BATEMAN, Nicholas, W.
IPC分类号： G01N33/536
摘要： This patent application discloses and describes proteins found to be differentially expressed between primary tumor breast cancer cells histologicaly defined as early stage (stage 0) breast cancer and primary breast cancer cells histologicaly defined as late stage (stage 3) breast cancer. These proteins can be used either individually or in specific combinations in diagnostic and prognostic protein assays on various biological samples from breast cancer patients to indicate the that a breast cancer patient's cancer is in an early, non- aggressive stage or in a late, aggressive stage. Determination of differential expression of these proteins can also be useful for indicating additional therapies to combat the aggressiveness of late stage breast cancer. The full length intact proteins can be assayed or peptides derived from these proteins can be assayed as reporters for these proteins. These proteins can also be identified as "companion diagnostic" proteins, wherein the differentially expressed proteins that are used as diagnostic and prognostic indicators can also be used as targets for therapeutic intervention of breast cancer. Also disclosed and described herein are isotope labeled versions of peptides from the proteins.

5. 发明申请

WO2012092529A3 PROTEIN BIOMARKERS OF RECURRENT BREAST CANCER 审中-公开
标题翻译：复发性乳腺癌的蛋白质生物标志物
公开(公告)号：WO2012092529A3
公开(公告)日：2012-08-23
申请号：PCT/US2011067996
申请日：2011-12-29
申请人： EXPRESSION PATHOLOGY INC , KRIZMAN DAVID B , DARFLER MARLENE M , CONRADS THOMAS P , HOOD BRIAN L , BATEMAN NICHOLAS W
发明人： KRIZMAN DAVID B , DARFLER MARLENE M , CONRADS THOMAS P , HOOD BRIAN L , BATEMAN NICHOLAS W
IPC分类号： G01N33/536
CPC分类号： G01N33/57415 , C12Q1/6886 , C12Q2600/118 , C12Q2600/156 , G01N2800/52
摘要： This patent application discloses and describes proteins found to be differentially expressed between primary tumor breast cancer cells that did not give rise to recurrent breast cancer disease after initial diagnosis and primary breast cancer cells that did give rise to recurrent breast cancer disease after initial diagnosis. These proteins can be used either individually or in specific combinations in diagnostic and prognostic protein assays on various biological samples from breast cancer patients to indicate the likelihood that a breast cancer patient's cancer will recur after initial diagnosis and treatment. Determination of differential expression of these proteins can also be useful for indicating additional therapies to combat the likelihood of recurrent breast cancer. The full length intact proteins can be assayed or peptides derived from these proteins can be assayed as reporters for these proteins. These proteins can also be identified as "companion diagnostic" proteins, wherein the differentially expressed proteins that arc used as diagnostic and prognostic indicators can also be used as targets for therapeutic intervention of breast cancer. Also disclosed and described herein are isotope labeled versions of peptides from the proteins.
摘要翻译：该专利申请公开并描述了在初次诊断后未导致复发性乳腺癌疾病的原发性肿瘤乳腺癌细胞与在初始诊断后确实引起复发性乳腺癌疾病的原发性乳腺癌细胞之间差异表达的蛋白质。这些蛋白质可以单独使用或以特定的组合方式用于来自乳腺癌患者的各种生物样品的诊断和预后蛋白质测定，以指示乳腺癌患者的癌症在初次诊断和治疗后会复发的可能性。确定这些蛋白质的差异表达也可用于指示额外的治疗方法来对抗乳腺癌复发的可能性。可以测定全长完整蛋白质，或者可以将这些蛋白质衍生的肽分析为这些蛋白质的报道分子。这些蛋白质也可以被鉴定为“伴侣诊断”蛋白质，其中用作诊断和预后指标的差异表达蛋白质也可以用作乳腺癌治疗干预的靶标。本文还公开和描述了来自蛋白质的肽的同位素标记形式。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式